

## Summary of Consolidated Financial Results for the three months Ended June 30, 2011

August 3, 2011

Listed company name : Sysmex Corporation  
 Code : 6869  
 Listed stock exchanges : Tokyo Stock Exchange  
 Osaka Securities Exchange  
 URL : <http://www.sysmex.co.jp>  
 Company representative : Hisashi Ietsugu, President and CEO  
 Contact : Yukitoshi Kamao, Executive Vice President,  
 Corporate Business Administration  
 Phone : 078(265)-0500  
 Scheduled date for filing of quarterly report : August 12, 2011  
 Scheduled date for dividend payment : —  
 Preparation of supplementary material for quarterly earnings : Yes  
 Holding of quarterly earnings announcement : Yes

(Unit: Millions of Yen)

### 1. Results for the three months ended June 30, 2011

#### (1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating income		Ordinary income		Net income	
Three months ended Jun. 30, 2011	30,758	10.3%	3,051	(9.6%)	2,977	(0.9%)	1,658	(6.3%)
Three months ended Jun. 30, 2010	27,894	11.6%	3,375	107.1%	3,004	69.4%	1,770	57.7%

	Net income per share (Yen)	Diluted net income per share (Yen)
Three months ended Jun. 30, 2011	16.15	16.11
Three months ended Jun. 30, 2010	17.26	17.22

Note:

Comprehensive income: 1,284 million yen(—%) for the three months ended June 30, 2011; (742) million yen(—%) for June 30, 2010.

#### (2) Financial condition

	Total assets	Net assets	Equity Ratio	Net assets per share (Yen)
As of Jun. 30, 2011	125,574	93,908	74.2%	907.40
As of Mar. 31,	130,059	94,232	71.9%	910.68

Note:

Equity capital: 93,209 million yen as of June 30, 2011; 93,533 million yen as of March 31, 2011

### 2. Dividends (The year ended March 31, 2011 and the year ending March 31, 2012)

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, Year ending Mar. 31,	—	28.00	—	32.00	60.00
Year ending Mar. 31, 2012 (Forecast)	—	15.00	—	15.00	30.00

Note:

Revision of dividends forecast for this period: No

### 3. Business forecast for the year ending March 31, 2012

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating income		Ordinary income		Net income		Net income per share (Yen)
Three months ending Sep. 30, 2011	65,000	8.2%	9,800	2.5%	10,000	11.5%	6,100	10.9%	59.38
Year ending Mar. 31, 2012	138,000	10.7%	20,500	12.1%	20,700	15.1%	13,000	13.9%	126.56

Note:

Revision of business forecast for this period: No

### 4. Other information

- (1) Changes in significant consolidated subsidiaries(which resulted in changes in scope of consolidation): No
- (2) Application of special accounting policy for quarterly financial reporting: No
- (3) Changes in accounting policies, accounting estimates and restatement of corrections
  - 1) Changes in accounting policies resulting from the revision of the accounting standards and other regulations: Yes
  - 2) Other changes in accounting policies: No
  - 3) Changes in accounting estimates: No
  - 4) Restatement of corrections: No
- (4) Number of shares outstanding (Ordinary shares)
  - 1) Number of shares outstanding at the end of each fiscal period (including treasury stock):  
102,939,816 shares as of Jun. 30, 2011; 102,923,616 shares as of Mar. 31, 2011
  - 2) Number of treasury stock at the end of each fiscal period:  
217,650 shares as of Jun. 30, 2011; 216,616 shares as of Mar. 31, 2011
  - 3) Average number of outstanding stock for each period (cumulative):  
102,717,053 shares three months ended Jun. 30, 2011; 102,577,278 shares three months ended Jun. 30, 2010

\*It is under the review procedure based on the Financial Instruments and Exchange Act at the time of disclosure of this report.

\*The above estimates are based on information available to the company on the date of the report's announcement. Due to unforeseen circumstances, however, actual results may differ from such estimates.

[Financial performance]

#### 1. Performance analysis

During the first quarter of the fiscal year ending March 31, 2012, the Japanese economy was affected by the ongoing effects of the Great East Japan Earthquake, which struck on March 11, 2011. Affected by supply chain interruptions and electric power shortages, corporate activity waned and personal consumption grew sluggish. These factors, combined with rising raw materials prices and ongoing yen appreciation, prompted concerns of economic stagnation and shrouded the future in uncertainty. In Europe and the United States, the employment situation improved and economies trended toward recovery. The global economic outlook remains unclear, however, owing to such factors as unrest in the Middle East and Africa and rising gasoline prices—causing customer confidence to fall—as well as government financial crises. In emerging markets, meanwhile, overall economic expansion remains firm, despite uncertainties stemming from decelerating economic growth in China and rising consumer prices.

On the healthcare front, earnings and profits at medical institutions in Japan are beginning to improve, prompted by the restructuring of public hospitals and revisions in medical remuneration. In advanced countries in Europe and North America, efforts are underway to reduce healthcare costs and reform medical systems. In the United States, dispute continues about a medical reform bill that aims to reduce the number of people without medical insurance. In China, medical system reform that is underway, including to the medical insurance system, aims to build infrastructures that provide uniform medical services in cities and farming villages throughout the country.

#### Net Sales by Destination

(First Quarters of Fiscal Years to March 31)	2011 1Q		2012 1Q		YoY (Previous period = 100%)
	Amount (Millions of Yen)	Percentage of Total (%)	Amount (Millions of Yen)	Percentage of Total (%)	
Japan	7,126	25.6	7,828	25.5	109.9
Americas	6,444	23.1	6,434	20.9	99.8
Europe	8,472	30.4	9,648	31.4	113.9
China	3,970	14.2	4,989	16.2	125.6
Asia Pacific	1,881	6.7	1,858	6.0	98.8
Overseas subtotal	20,768	74.4	22,930	74.5	110.4
Total	27,894	100.0	30,758	100.0	110.3

In its mainstay hematology field, the Sysmex Group launched the new top-end XN-Series of multiparameter automated hematology analyzers in Japan, ahead of other countries. The series is designed for sale across all regions, and sales will commence by country, as approved. In Russia, Sysmex established a subsidiary in the preceding fiscal year, which began assisting distributors in their sales and support services in the first quarter.

With regard to the impact of the Great East Japan Earthquake on the Sysmex Group, although some structures and facilities at our offices in the Tohoku region sustained damage, our product supply, sales and support networks were essentially unaffected.

In Japan, management improvements accompanying healthcare reforms resulted in steady capital investment by large-scale healthcare institutions. This situation and our ongoing efforts to promote solutions led to solid sales, as well as strong performance in terms of receiving major orders. As a result, we posted net sales of ¥7,828 million, up 9.9% from the same period of the previous fiscal year.

In overseas markets, we made steady progress in the strengthening of sales and support structures and the provision of solutions. As a result, sales moved steadily upward on a local currency basis due to increased sales of instruments and diagnostic reagents. Consequently, despite major yen appreciation the Group's overseas sales were ¥22,930 million, up 10.4% year on year. The overseas sales ratio was 74.5%, up 0.1 percentage point from the same period of the previous fiscal year.

Income, however, was down year on year, owing to the impact of substantial yen appreciation against the U.S. dollar.

As a result, during the year the Group recorded consolidated net sales of ¥30,758 million, up 10.3%. Operating income fell 9.6%, to ¥3,051 million; ordinary income decreased 0.9%, to ¥2,977 million; and net income declined 6.3%, to ¥1,658 million.

#### Performance by segment

##### (1) Japan

Performance remained robust in the hematology field, our main business domain, as well as in the hemostasis, urinalysis and laboratory information systems, owing to our perseverance in presenting solutions to customers paid off in the form of large orders. These factors contributed to a 10.1% rise in net sales compared with the corresponding period of the preceding fiscal year, to ¥8,470 million.

Despite the negative effects on income of yen appreciation, we posted operating income of ¥1,050 million, up 146.7% year on year. This rise was the result of robust domestic sales and an increase in export sales to Group companies, including the impact of a revision in intragroup transaction prices.

##### (2) Americas

In the United States, sales grew as a result of our focus on developing direct sales and support networks, as well as our success in promoting solutions that meet customer needs, which generated strong sales to integrated health networks (IHNs). In addition, economic recovery in Central and South America led to robust sales, centering on bids. However, owing to the negative effects of yen appreciation, sales in the Americas fell 1.8%, to ¥6,212 million.

The effects of yen appreciation, the higher cost of sales resulting from a revision in intragroup transaction prices and an increase in selling, general and administrative expenses stemming from efforts to reinforce our sales and support operations prompted a 33.0% decrease in operating income, to ¥459 million.

##### (3) Europe

In addition to enhancing our direct sales and support activities, we continued in our efforts to propose solutions, resulting in robust sales centered in the hematology field. In the United Kingdom and France, the number of instrument installations increased in line with our acquisition of new customers, pushing up sales of diagnostic reagents. As a result, sales in Europe were up 13.4% year on year, to ¥9,604 million.

The effects of higher sales and a lower cost of sales ratio compensated for an increase in selling, general and administrative expenses to enhance our sales and support structure, prompting operating income to rise 10.1%, to ¥1,334 million.

#### (4) China

In China, sales surged 25.6%, to ¥4,989 million. Behind these solid results were substantially higher sales of instruments and diagnostic reagents in the hematology, hemostasis and urinalysis fields.

Operating income rose 2.6%, to ¥951 million, as higher sales compensated for higher cost of sales resulting from a revision in intragroup transaction prices.

#### (5) Asia Pacific

Owing to major new orders in Indonesia and Malaysia in the preceding fiscal year, the number of installed instruments increased, prompting a major rise in sales of diagnostic reagents. Furthermore, sales were up substantially in India, centered on the hematology field. However, the sales increase for the region was relatively small, rising 3.7%, to ¥1,482 million, owing to the comparison against the same period of the preceding fiscal year, when sales surged temporarily owing to the receipt of a major new order.

Owing to the higher cost of sales resulting from a revision in intragroup transaction prices and an increase in selling, general and administrative expenses, operating income fell 79.3%, to ¥40 million.

## 2. Financial conditions analysis

### (1) Assets, liabilities and net assets

As of June 30, 2011, total assets amounted to ¥125,574 million, down ¥4,485 million from the end of the previous fiscal year. Major factors included a ¥4,001 million drop in cash and deposits.

Meanwhile, total liabilities were down ¥4,160 million, to ¥31,666 million. The main contributors to this decrease were a ¥1,246 million decline in trade notes and accounts payable, a ¥1,853 million decrease in income taxes payable and ¥1,512 million lower provision for bonuses.

Total net assets came to ¥93,908 million at the end of the first quarter, down ¥324 million. The principal reason for this fall was a ¥415 million decrease in foreign currency translation adjustments. The equity ratio as of June 30, 2011, was 74.2%, up 2.3 percentage points from the end of the previous fiscal year.

### (2) Cash flows

As of June 30, 2011, cash and cash equivalents amounted to ¥14,920 million, down ¥3,995 million from March 31, 2011. Cash flows from various activities are described in more detail below.

#### (Operating cash flow)

Net cash provided by operating activities was ¥1,453 million, up ¥108 million. As principal factors, income before income taxes provided ¥2,965 million, ¥142 million more than during the preceding quarter, and a decrease in trade notes and accounts receivable provided ¥2,364 million, (¥900 million more than in the first quarter of the preceding fiscal year). However, income taxes paid used ¥2,865 million, ¥913 million more than in the first quarter of the preceding fiscal year.

(Investing cash flow)

Net cash used in investing activities was ¥4,053 million, ¥2,395 million more than in the first quarter of the preceding fiscal year. The main use of cash was purchases of property, plant and equipment, which used ¥1,630 million, ¥356 million more than in the first quarter of the previous year. In addition, expenditures for the transfer of business used ¥1,900 million.

(Financing cash flow)

Net cash used in financing activities amounted to ¥1,229 million, ¥1,941 million more than was used in these activities in the first quarter of the previous year. In this category, a net increase in short-term loans payable provided ¥575 million, ¥1,885 less than in the first quarter of the preceding fiscal year.

### 3. Consolidated financial forecast

During the first quarter of the fiscal year ending March 31, 2012, net sales were up year on year, but owing to such factors as major yen appreciation against the U.S. dollar, income fell, compared with the first quarter of the preceding year. However, we are enjoying solid overseas sales growth on a local currency basis, and performance is largely in line with our expectations. Although exchange rate movements and the economic slowdown resulting from Europe's sovereign debt crisis are causes for uncertainty, we expect our performance to progress as planned. Consequently, we maintain unchanged the first-half and full-year consolidated performance forecasts we announced on May 10, 2011.

## Consolidated Balance Sheets

(Unit: Millions of Yen)

Items	As of Mar. 31, 2011	As of June. 30, 2011
	Amount	Amount
<b>(Assets)</b>		
<b>I Current assets</b>		
Cash and deposits	18,950	14,949
Notes and accounts receivable-trade	32,063	29,481
Short-term investment securities	178	246
Merchandise and finished goods	14,329	14,775
Work in process	1,733	1,786
Raw materials and supplies	3,748	3,966
Others	9,299	9,297
Allowance for doubtful accounts	(370)	(356)
<b>Total current assets</b>	<b>79,931</b>	<b>74,147</b>
<b>II Noncurrent assets</b>		
<b>Property, plant and equipment</b>		
Buildings and structures, net	15,232	15,288
Others	20,999	21,079
<b>Total Property, plant and equipment</b>	<b>36,231</b>	<b>36,368</b>
<b>Intangible assets</b>		
Goodwill	1,830	2,970
Others	4,816	4,786
<b>Total Intangible assets</b>	<b>6,646</b>	<b>7,757</b>
<b>Total Investments and other assets</b>	<b>7,250</b>	<b>7,301</b>
<b>Total Noncurrent assets</b>	<b>50,128</b>	<b>51,427</b>
<b>Total assets</b>	<b>130,059</b>	<b>125,574</b>
<b>(Liabilities)</b>		
<b>I Current liabilities</b>		
Notes and accounts payable-trade	11,574	10,327
Short-term loans payable	310	882
Income taxes payable	2,728	875
Provision for bonuses	3,277	1,765
Provision for directors' bonuses	207	64
Provision for product warranties	128	123
Others	12,764	12,873
<b>Total current liabilities</b>	<b>30,992</b>	<b>26,912</b>
<b>II Noncurrent liabilities</b>		
Long-term loans payable	11	9
Provision for retirement benefits	751	916
Provision for directors' retirement benefits	160	160
Others	3,910	3,668
<b>Total Noncurrent liabilities</b>	<b>4,834</b>	<b>4,754</b>
<b>Total liabilities</b>	<b>35,827</b>	<b>31,666</b>
<b>(Net assets)</b>		
<b>I Shareholders' equity</b>		
Capital stock	9,041	9,064
Capital surplus	13,981	14,004
Retained earnings	74,662	74,677
Treasury stock	(252)	(255)
<b>Total shareholders' equity</b>	<b>97,433</b>	<b>97,491</b>
<b>II Accumulated other comprehensive income</b>		
Valuation difference on available-for-sale securities	185	207
Deferred gains or losses on hedges	(13)	(2)
Foreign currency translation adjustment	(4,071)	(4,486)
<b>Total accumulated other comprehensive income</b>	<b>(3,899)</b>	<b>(4,281)</b>
<b>III Subscription rights to shares</b>	<b>600</b>	<b>592</b>
<b>IV Minority interests</b>	<b>98</b>	<b>106</b>
<b>Total net assets</b>	<b>94,232</b>	<b>93,908</b>
<b>Total liabilities and net assets</b>	<b>130,059</b>	<b>125,574</b>

(Note) fractions of one million yen are rounded off

## Consolidated Statements of Income

(Unit: Millions of Yen)

Items	Three months ended June. 30, 2010	Three months ended June. 30, 2011
	Amount	Amount
<b>I Net sales</b>	27,894	30,758
<b>II Cost of sales</b>	9,778	11,692
Gross profit	18,116	19,066
<b>III Selling, general and administrative expenses</b>	14,740	16,014
Operating income	3,375	3,051
<b>IV Non-operating income</b>		
Interest income	26	32
Dividends income	21	21
Income from investment real estate	94	95
Others	44	73
<b>Total non-operating income</b>	187	223
<b>V Non-operating expenses</b>		
Interest expenses	29	21
Equity in losses of affiliates	15	15
Maintenance cost of investment real estate	34	34
Foreign exchange losses	467	219
Others	11	6
<b>Total non-operating expenses</b>	558	296
Ordinary income	3,004	2,977
<b>VI Extraordinary profits</b>		
Gain on sales of noncurrent assets	1	10
Reversal of allowance for doubtful accounts	8	-
<b>Total extraordinary profits</b>	9	10
<b>VII Extraordinary loss</b>		
Loss on sales and retirement of noncurrent assets	4	17
Loss on adjustment for changes of accounting standard for asset retirement obligations	187	-
Loss on valuation of membership	-	4
Others	0	-
<b>Total extraordinary loss</b>	191	22
<b>Income before income taxes and minority interest</b>	2,823	2,965
Income taxes-current	1,059	1,176
Income taxes-deferred	(10)	129
<b>Total income taxes</b>	1,048	1,306
<b>Income before minority interests</b>	1,774	1,659
<b>Minority interest</b>	3	0
<b>Net income</b>	1,770	1,658

(Note) fractions of one million yen are rounded off



## Consolidated Statements of Comprehensive Income

(Unit: Millions of Yen)

Items	Three months ended June. 30, 2010	Three months ended June. 30, 2011
<b>Income before minority interests</b>	1,774	1,659
<b>Other comprehensive income</b>		
Valuation difference on available-for-sale securities	(82)	21
Deferred gains or losses on hedges	19	11
Foreign currency translation adjustment	(2,454)	(408)
<b>Total other comprehensive income</b>	<b>(2,516)</b>	<b>(374)</b>
<b>Comprehensive income</b>	<b>(742)</b>	<b>1,284</b>
Comprehensive income attributable to owners of the parent	(739)	1,276
Comprehensive income attributable to minority interests	(3)	7

(Note) fractions of one million yen are rounded off

## Consolidated Statements of Cash Flows

(Unit: Millions of Yen)

Items	Three months ended June. 30, 2010	Three months ended June. 30, 2011
<b>I Net cash provided by (used in) operating activities</b>		
Income before income taxes	2,823	2,965
Depreciation and amortization	1,823	1,827
Loss on adjustment for changes of accounting standard for asset retirement obligations	187	-
Decrease (increase) in notes and accounts receivable-trade	1,463	2,364
Decrease (increase) in inventories	(246)	(984)
Increase (decrease) in notes and accounts payable-trade	(1,256)	(1,162)
Others	(1,511)	(726)
<b>Subtotal</b>	3,283	4,283
Interest and dividends received	42	48
Interest expenses paid	(28)	(14)
Income taxes paid	(1,952)	(2,865)
<b>Net cash provided by (used in) operating activities</b>	1,345	1,453
<b>II Net cash provided by (used in) investment activities</b>		
Purchase of property, plant and equipment	(1,274)	(1,630)
Purchase of intangible assets	(322)	(410)
Payments for transfer of business	-	(1,900)
Others	(60)	(111)
<b>Net cash provided by (used in) investment activities</b>	(1,657)	(4,053)
<b>III Net cash provided by (used in) financing activities</b>		
Net increase (decrease) in short-term loans payable	2,460	575
Repayment of long-term loans payable	(3)	(1)
Cash dividends paid	(1,588)	(1,643)
Others	(156)	(160)
<b>Net cash provided by (used in) financing activities</b>	711	(1,229)
<b>IV Effect of exchange rate change on cash and cash equivalents</b>	(547)	(166)
<b>V Net increase (decrease) in cash and cash equivalents</b>	(148)	(3,995)
<b>VI Cash and cash equivalents at beginning of term</b>	13,812	18,915
<b>VII Cash and cash equivalents at end of term</b>	13,663	14,920

(Note) fractions of one million yen are rounded off

## Segment Information

### 1. Information on sales and income by geographic segment reported

Three months ended June 30, 2010

(Unit: Millions of Yen)

	Japan	Americas	Europe	China	Asia Pacific	Total	Reconciliations	Consolidated
Sales and Operating income								
Sales								
Net Sales to outside customers	7,695	6,328	8,470	3,970	1,429	27,894	-	27,894
Inter-area transfer	7,471	0	69	1	36	7,580	(7,580)	-
Total net sales	15,166	6,328	8,540	3,972	1,465	35,474	(7,580)	27,894
Operating income	425	685	1,212	926	194	3,445	(69)	3,375

Note: Reconciliations principally consist of intersegment transfers.

Three months ended June 30, 2011

(Unit: Millions of Yen)

	Japan	Americas	Europe	China	Asia Pacific	Total	Reconciliations	Consolidated
Sales and Operating income								
Sales								
Net Sales to outside customers	8,470	6,212	9,604	4,989	1,482	30,758	-	30,758
Inter-area transfer	9,005	0	120	0	37	9,165	(9,165)	-
Total net sales	17,475	6,213	9,725	4,990	1,519	39,924	(9,165)	30,758
Operating income	1,050	459	1,334	951	40	3,835	(784)	3,051

Note: Reconciliations principally consist of intersegment transfers.